Overview
Supported by
Preliminary Results of a Phase 2 Multicentre Study of Linac-based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS) – David Pryor
Assessing the safety and learning curve of hydrogel spacer device placement in a regional centre – Alexander Nesbitt
Five years of focal irreversible electroporation for prostate cancer – What have we learned? – Alexandar Blazevski
Survivorship from Robotic Assisted Laparoscopic Prostatectomy (RALP) considering Lower Urinary Tract Symptoms (LUTS) – Andrew Strahan
Pathological characteristics of prostate cancer in younger men – James Macneil
Distribution of prostate cancer treatment options in newly diagnosed patients – Yeji Ham
Gleason score and calendar month influence likelihood of discussion at Multidisciplinary meeting – Yeji Ham
Primary Androgen Deprivation Therapy as Monotherapy in Unfavourable Intermediate and High Risk Localised Prostate Cancer – A Singaporean Single-centre Perspective – Han Jie Lee
Androgen Receptor (AR) Anomalies and Efficacy of Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From the Phase 3 SPARTAN Study – Paul N. Mainwaring
PSA Age-Specific Reference Ranges for Puerto Rican Prostate Cancer Patients – Ernesto Esteban
PIRADS 3 lesions: Should we bother with MRI-Ultrasound fusion biopsy – Sean Heywood
MRI-TRUS fusion biopsy has a high rate of down grading of grade group 3 and 4 lesions – Sean Heywood
Biopsy outcomes for PIRADS 3 patients in Melbourne – Daniel Costello
Oncologic outcomes of Gleason 3+4 Prostate Cancer: A retrospective analysis of experience in Victoria – Homayoun (Homi) Zargar
Implementation of an electronic Patient Reported Outcome system in the Prostate Clinic at the Vancouver Prostate Centre – Tia (Celestia) Higano
